Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration

Bergendal, Annica, Kieler, Helle, Sundström, Anders, Hirschberg, Angelica Lindén, Kocoska-Maras, Ljiljana · 2016 · Menopause

Abstract

Objective: The aim of the study was to assess the risk of venous thromboembolism (VTE) associated with systemic hormone therapy according to type and to route of administration and the risk of VTE associated with locally administered estrogen. Methods: In this case-control study, conducted in Sweden between 2003 and 2009, we included 838 cases of VTE and 891 controls with a mean age of 55 years. Controls were matched by age to the cases and randomly selected from the population. We used logistic regression to calculate odds ratios (ORs) with 95% CIs and adjusted for smoking, body mass index, and immobilization. Results: Current use of any hormone therapy was associated with an increased risk of VTE (OR 1.72, 95% CI 1.34-2.20). For estrogen in combination with progestogen the OR was 2.85 (95% CI 2.08-3.90), and for estrogen only the OR was 1.31 (95% CI 0.78-2.21). In orally administered estrogen combined with progestogen, the OR was slightly, but not significantly, higher among users of medroxyprogesterone acetate (OR 2.94, 95% CI 1.67-5.36) than among norethisterone acetate users (OR 2.55, 95% CI 1.50-3.40). Transdermal estrogen combined with progestogen was not associated with VTE risk (crude and imprecise ORs ranging from 0.87 to 1.16). For local effect of estrogen, there was no association with VTE risk (OR 0.69, 95% CI 0.43-1.10). Conclusions: The risk of VTE risk is higher in users of systemic combined estrogen–progestogen treatment than in users of estrogen only. Furthermore, the risk of VTE was lower for women who used local estrogen than among those using oral estrogen only. Transdermal estrogen only treatment and estrogen for local effect seem not to be related to an increased risk of VTE.

Overview

Integrity signals

Registry

Crossref · 10.1097/gme.0000000000000611

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 90

Metadata

Authors
Bergendal, A., Kieler, H., Sundström, A., Hirschberg, A. L., & Kocoska-Maras, L.
Affiliations
  • Karolinska Institutet (SE)
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Venue
Menopause
Published
2016-06
Volume
23
Issue
6
Pages
593-599
ISSN
  • 1072-3714 (ISSN-L)
  • 1530-0374
OpenAlex
W2327965756
Cited by
90
References
32
Citations by year
2026: 10 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 7 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 14 · 2016: 3
FWCI
12.23
Type
journal article
Language
en
Open access
closed
Locations
  • Menopause The Journal of The North American Menopause Society (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
venous thromboembolism, hormone therapy, estrogen-progestin combination, estrogen-only therapy, transdermal estrogen, route of administration, medroxyprogesterone acetate, norethisterone acetate, peri- and postmenopausal women, thrombosis risk
MeSH terms
Norethindrone Acetate, Administration, Cutaneous, Administration, Oral, Estrogens, Female, Humans, Menopause, Middle Aged, Norethindrone, Progestins, Risk Factors, Sweden, Vagina, Estrogen Replacement Therapy, Logistic Models, Odds Ratio, Case-Control Studies, Medroxyprogesterone Acetate, Postmenopause, Perimenopause, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. https://app.cochat.ai/papers/10.1097/gme.0000000000000611
The paper
Bergendal, A., Kieler, H., Sundström, A., Hirschberg, A. L., & Kocoska-Maras, L. (2016). Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause. https://doi.org/10.1097/gme.0000000000000611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.